Factors VIII and IX gene therapy - Targeted Genetics

Drug Profile

Factors VIII and IX gene therapy - Targeted Genetics

Alternative Names: TgAAV-FVIII

Latest Information Update: 05 Mar 2008

Price : $50

At a glance

  • Originator Targeted Genetics
  • Developer Targeted Genetics Corporation
  • Class
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Haemophilia A; Haemophilia B

Most Recent Events

  • 18 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) have been added to the Haemotological Disorders and Gene Therapies pharmacodynamics sections
  • 03 Mar 2003 Suspended - Preclinical for Haemophilia B in USA (unspecified route)
  • 03 Mar 2003 Suspended - Preclinical for Haemophilia A in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top